A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Mar 2018
At a glance
- Drugs ENT 01 (Primary)
- Indications Constipation
- Focus Adverse reactions
- Acronyms RASMET
- Sponsors Enterin
- 22 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2018 Planned end date changed from 1 Dec 2017 to 1 Apr 2018.
- 02 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.